AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27577237
Drug: PfAMA1-FVO vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PfAMA1-FVO vaccine (50 µg)
Trial: 27577237
Drug: Control vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control vaccine (tetanus toxoid)
Trial: 24388792
Drug: One-day bowel
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-day bowel preparation (fiber-free diet and 3 L of polyethylene glycol on day 0)
Trial: 24388792
Drug: Two-day bowel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-day bowel preparation (liquid diet and 3 L of polyethylene glycol in the evening of day -1, and 1L of PEG in the early morning of day 0)
Trial: 24388792
Drug: One-day bowel
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-day bowel preparation
Trial: 24388792
Drug: Two-day bowel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-day bowel preparation
Trial: 23176073
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg pramipexole
Trial: 10719133
Drug: Blood pressure
RxNorm normalized name: Blood Pressure Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure biofeedback treatment (BF) once a week for a total of four sessions
Trial: 10719133
Drug: Blood pressure
RxNorm normalized name: Blood Pressure Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure biofeedback treatment (BF)
Trial: 8646865
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate cream, 0.05%, twice-daily (BID) application
Trial: 8646865
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate cream, 0.05%, once-daily (QD) application
Trial: 1906692
Drug: Immediate intravenous
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate intravenous beta-blocker therapy
Trial: 3994783
Drug: Ciprofibrate (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofibrate (100 mg daily, single administration)
Trial: 3994783
Drug: Fenofibrate (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (300 mg daily, 3 administrations)
Trial: 3994783
Drug: Ciprofibrate (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofibrate (100 or 200 mg/day after 9 months)
Trial: 3994783
Drug: Fenofibrate (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (400 mg/day after 9 months)
Trial: 22339105
Drug: Far infrared
RxNorm normalized name: Menthol/Methyl Salicylate 3%-0.5% Topical application Patch, Extended Release [GOLDEN SUNSHINE FAR INFRARED HOT HERBAL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Far infrared rays (FIR) thermal therapy applied on acupoints ST37, ST38, ST39, ST40 from day 3 to day 5 post-surgery
Trial: 18642381
Drug: Voice exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voice exercise therapy (VE)
Trial: 16926331
Drug: Endovascular brachytherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular brachytherapy (EBT) with an iridium 192 source, prescribed dose of 12 Gy at 3 mm from the source axis
Trial: 9651260
Drug: Intravenous heroin
RxNorm normalized name: heroin
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heroin
Trial: 11041310
Drug: Oral opiates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral opiates
Trial: 11041310
Drug: Mixed regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed regimens (intravenous heroin and oral opiates)
Trial: 11041310
Drug: Alternative treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative treatments (methadone maintenance, detoxification)
Trial: 1418021
Drug: Intraarticular injections
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraarticular injections of glycosaminoglycan polysulfate (GAGPS) plus basic conservative treatment
Trial: 1418021
Drug: Physiologic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiologic saline injections plus basic conservative treatment
Trial: 1418021
Drug: Basic conservative
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic conservative treatment alone (6-week program of quadriceps muscle exercise, elimination of symptom-producing activities, and oral NSAIDs)
Trial: 26602795
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (EVLA and SFL/S)
Trial: 20197703
Drug: Higher fasting
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher fasting insulin levels
Trial: 17656271
Drug: Mepivacaine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepivacaine (30 mg in 1 mL saline)
Trial: 17656271
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Mepivacaine and Morphine (30 mg mepivacaine and 1 mg morphine in 1 mL saline)
Trial: 17656271
Drug: Morphine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (1 mg in 1 mL saline)
Trial: 17656271
Drug: Saline control
RxNorm normalized name: GLYCERIN 0.53 g in 1 mL CUTANEOUS INJECTION [Glycerol-Saline Control]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline control (1 mL saline)
Trial: 7758179
Drug: Testosterone cypionate
RxNorm normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone cypionate 200 mg IM given twice, 2 weeks apart
Trial: 2321713
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of lytic cocktail (0.05 ml/kg, max 2.0 ml)
Trial: 2321713
Drug: Rectal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal administration of lytic cocktail (0.07 ml/kg, max 2.8 ml)
Trial: 6968567
Drug: ICI 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 35 868, dose: 2 mg kg‐1, injected over 30 s
Trial: 6968567
Drug: Althesin, dose:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Althesin, dose: 0.05 ml kg‐1, injected over 30 s
Trial: 31940991
Drug: Paclitaxel-based chemotherapy
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel-based chemotherapy
Trial: 31940991
Drug: Non-paclitaxel-based chemotherapy
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Non-paclitaxel-based chemotherapy
Trial: 30732143
Drug: Interactive voice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive voice response system (IVRS) providing automatic calls in 3 categories: educational, medication adherence, and reminders.
Trial: 9322987
Drug: Aspirin, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, 100 mg/d, starting at 12 to 16 weeks of gestation, taken at time 1 (on awakening)
Trial: 9322987
Drug: Aspirin, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, 100 mg/d, starting at 12 to 16 weeks of gestation, taken at time 2 (8 hours after awakening)
Trial: 9322987
Drug: Aspirin, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, 100 mg/d, starting at 12 to 16 weeks of gestation, taken at time 3 (before bedtime)
Trial: 2942203
Drug: Tamoxifen 30
RxNorm normalized name: tamoxifen 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 30 mg per day alternating every two weeks with medroxyprogesterone acetate (MPA) 1,000 mg per day orally.
Trial: 2942203
Drug: Tamoxifen 30
RxNorm normalized name: tamoxifen 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 30 mg per day and after relapse, high dosage of MPA alone.
Trial: 25192980
Drug: Active rTMS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active rTMS combined with active venlafaxine (150‐225 mg/day)
Trial: 25192980
Drug: Sham rTMS
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham rTMS combined with active venlafaxine (150‐225 mg/day)
Trial: 22411689
Drug: DGLA-enriched oil
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DGLA-enriched oil (450 mg as free DGLA) for 4 weeks
Trial: 11949798
Drug: Scotchbond 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scotchbond 1 (dentin bonding agent)
Trial: 9490250
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for Dupuytren contracture
Trial: 3223639
Drug: 100 micrograms.kg-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 micrograms.kg-1 morphine (group M)
Trial: 3223639
Drug: 0.1 ml.kg-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 ml.kg-1 normal saline placebo (group T)
Trial: 30115911
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg valproate
Trial: 28508107
Drug: Memantine add-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine add-on treatment
Trial: 23047118
Drug: GS-9451 60
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GS-9451 60 mg/day
Trial: 23047118
Drug: GS-9451 200
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GS-9451 200 mg/day
Trial: 23047118
Drug: GS-9451 400
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GS-9451 400 mg/day
Trial: 23047118
Drug: GS-9451 200
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GS-9451 200 mg/day (genotype 1b)
Trial: 18466075
Drug: Ezetimibe (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe (single dose with levothyroxine)
Trial: 11090557
Drug: 0.45% oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.45% oral saline
Trial: 11090557
Drug: No rehydration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No rehydration treatment
Trial: 8937491
Drug: Single administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single administration of DMDC at 200 mg/m2 (initial dose) increased to 450 mg/m2.
Trial: 8937491
Drug: Single repeated
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single repeated administration of DMDC at 300 mg/m2.
Trial: 8937491
Drug: 5-consecutive-day administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-consecutive-day administration of DMDC starting at 30 mg/m2/day increased to 40 mg/m2/day.
Trial: 8937491
Drug: All administration
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All administration schedules of DMDC.
Trial: 1530174
Drug: Clonidine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (75 micrograms), followed by an infusion of 18.75 micrograms/h
Trial: 17673455
Drug: Fresh sperm
RxNorm normalized name: herring sperm DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh sperm from control group (normal patients >10(5) spermatozoa/ml)
Trial: 11192874
Drug: ABT‐378 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT‐378 200 mg with ritonavir 100 mg every 12 h plus stavudine 40 mg and lamivudine 150 mg every 12 h (group I)
Trial: 11192874
Drug: ABT‐378 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT‐378 400 mg with ritonavir 100 or 200 mg plus stavudine and lamivudine every 12 h (group II)
Trial: 9626825
Drug: Hirudin (adjunctive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hirudin (adjunctive therapy)
Trial: 9626825
Drug: Heparin (adjunctive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (adjunctive therapy)
Trial: 3057956
Drug: Supplementary oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementary oral nutrition for 3 months (Group 1)
Trial: 28734660
Drug: CAN/AML combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAN/AML combination therapy (8 mg/5 mg)
Trial: 28734660
Drug: CAN/AML combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAN/AML combination therapy (16 mg/5 mg)
Trial: 28734660
Drug: CAN/AML combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAN/AML combination therapy (16 mg/10 mg)
Trial: 28734660
Drug: CAN (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAN (8 mg)
Trial: 28734660
Drug: AML (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AML (10 mg)
Trial: 28734660
Drug: AML (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AML (5 mg)
Trial: 21368745
Drug: Fresolimumab (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresolimumab (up to 4 mg/kg)
Trial: 14571754
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin 500 mg every 12 h
Trial: 14571754
Drug: Intravenous cefotaxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cefotaxime 2 g every 8 h
Trial: 14571754
Drug: Intravenous ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ceftriaxone 2 g every 24 h
Trial: 7492038
Drug: Adenosine as
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine as a standing-order medication
Trial: 7021071
Drug: Ibuprofen (1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (1600 mg, 400 mg every 6 hours)
Trial: 28662676
Drug: BB‐12® containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BB‐12® containing capsule (CAP)
Trial: 25037968
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) applied from the first day of the conditioning regimen until day 7 post-HSCT
Trial: 19364976
Drug: 1 portion
RxNorm normalized name: XMAB5871 (HUMANIZED ANTI-CD19 ANTIBODY WITH AN FC PORTION ENGINEERED FOR INCREASED AFFINITY (200- TO 400-FOLD OVER NATIVE IGG) TO FCGRIIB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 portion of fruit and vegetables daily
Trial: 19364976
Drug: 3 portions
RxNorm normalized name: XMAB5871 (HUMANIZED ANTI-CD19 ANTIBODY WITH AN FC PORTION ENGINEERED FOR INCREASED AFFINITY (200- TO 400-FOLD OVER NATIVE IGG) TO FCGRIIB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 portions of fruit and vegetables daily
Trial: 19364976
Drug: 6 portions
RxNorm normalized name: XMAB5871 (HUMANIZED ANTI-CD19 ANTIBODY WITH AN FC PORTION ENGINEERED FOR INCREASED AFFINITY (200- TO 400-FOLD OVER NATIVE IGG) TO FCGRIIB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 portions of fruit and vegetables daily
Trial: 11464225
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg elemental Cu/day as CuSO4
Trial: 11464225
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg elemental Cu/day as CuSO4
Trial: 7995323
Drug: Simultaneous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous treatment with piretanide
Trial: 7995323
Drug: Simultaneous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous treatment with ramipril
Trial: 3219881
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg piretanide
Trial: 7995323
Drug: Simultaneous administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous administration of ramipril and piretanide
Trial: 3376144
Drug: Alcohol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.5 ml/kg)
Trial: 30665722
Drug: CVT-301 (levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVT-301 (levodopa inhalation powder)
Trial: 24061990
Drug: IMRT-TP (Intensity-Modulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMRT-TP (Intensity-Modulated Radiation Therapy plus chemotherapy with docetaxel and cisplatin)
Trial: 24061990
Drug: IMRT (Simple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMRT (Simple Intensity-Modulated Radiation Therapy)
Trial: 15996667
Drug: Oxytocin infusion
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin infusion with arithmetic increase
Trial: 15996667
Drug: Oxytocin infusion
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin infusion with geometric increase
Trial: 12086732
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release Ibifen (200 mg)
Trial: 12086732
Drug: Orudis retard
RxNorm normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orudis retard (200 mg)
Trial: 12086732
Drug: Prompt release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prompt release Ibifen (100 mg, two 12-h doses)
Trial: 9864078
Drug: Gabapentin (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (mean daily dose: 3,646.15 mg)
Trial: 8666093
Drug: Sparfloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparfloxacin (400 mg loading dose, followed by 200 mg o.d.)
Trial: 8666093
Drug: Amoxycillin-clavulanic acid
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin-clavulanic acid (500/125 mg t.i.d.)
Trial: 8666093
Drug: Erythromycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (1 g b.i.d.)
Trial: 25691671
Drug: ET-B (bevacizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ET-B (bevacizumab 15 mg/kg every 3 weeks + endocrine therapy)
Trial: 19661810
Drug: HPV-16 therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV-16 therapeutic vaccine
Trial: 14765636
Drug: Topical fluoride
RxNorm normalized name: Carles 60 Second APF 1.23% Topical Fluoride Dental Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fluoride (0.5% fluoride ion) followed by argon laser
Trial: 11552048
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA, 50 mg/day)
Trial: 11552048
Drug: Dipyridamole (sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (sustained-release preparation 400 mg/day)
Trial: 8981292
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ASA and dipyridamole
Trial: 8471228
Drug: Intravenous rHuEPO
RxNorm normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous rHuEPO (IV)
Trial: 8471228
Drug: Subcutaneous rHuEPO
RxNorm normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous rHuEPO (SC)
Trial: 29910056
Drug: Allogeneic mesenchymal
RxNorm normalized name: Allogeneic mesenchymal precursor cell
DrugBank: Rexlemestrocel-L (DB17606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic mesenchymal stromal cells (allo‐MSCs) via 20 transendocardial injections
Trial: 29910056
Drug: Vehicle (placebo)
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (placebo) via 20 transendocardial injections
Trial: 24733462
Drug: BMS-791325 (100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-791325 (100, 300, 600, or 900 mg)
Trial: 24733462
Drug: BMS-791325 (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-791325 (900 mg)
Trial: 20466313
Drug: RCTs published
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCTs published in other journals (European Journal of Oral Sciences, Journal of Dentistry, Clinical Oral Investigations)
Trial: 17900584
Drug: Sacrospinous suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacrospinous suspension (SS)
Trial: 920496
Drug: Chlordiazepoxide treatment
RxNorm normalized name: Chlordiazepoxide
DrugBank: Chlordiazepoxide (DB00475)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlordiazepoxide treatment for alcohol withdrawal
Trial: 920496
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose ethanol treatment for alcohol withdrawal
Trial: 31573666
Drug: Topical skin
RxNorm normalized name: Betadine 7.5% Topical Skin Cleanser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical skin formulation PT1 (2 strains of C. acnes SLST type C3 and K8, 50% each)